Seven global elite firms have been called in to advise as EQT takes German-founded molecular testing company QIAGEN private in a deal that values the company at €10.8bn.
The bidder is a holding company indirectly owned by the EQT XI fund, with institutional investors the Abu Dhabi Investment Authority (ADIA) and Canada Pension Plan Investment Board (CPP) also behind the transaction.
